Observation of curative efficacy and prognosis following combination chemotherapy with celecoxib in the treatment of advanced colorectal cancer

Journal of International Medical Research

Volumn 39, Issue 6, 2011, Pages 2129-2140

  Jin, C H ^a   Wang, A H ^a   Chen, J M ^a   Li, R X ^a   Liu, X M ^a   Wang, G P ^a   Xing, L Q ^a  

^a HENAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Celecoxib; Colorectal cancer; Cyclooxygenase 2 inhibitors; Folfox4

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADVANCED CANCER; AGED; ANGINA PECTORIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CHEMOSENSITIZATION; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; ELECTROCARDIOGRAM; FEMALE; HEART ARRHYTHMIA; HEART INFARCTION; HEMATOCHEZIA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; LIVER FUNCTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MOUTH INFLAMMATION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; PERIPHERAL NEUROTOXICITY; PROGNOSIS; PROTEIN FUNCTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SURVIVAL RATE; THROMBOSIS; VOMITING;

EID: 84555206128     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900609     Document Type: Article

References (48)

1. Wang YG, Chen KX, Wu GL, et al: An analysis: colon cancer mortality in Tianjin, China, from 1981 to 2000. World J Gastroenterol 2005; 11: 895-898.
2. Crespi M: Models of screening program for colorectal cancer. Med Arh 2002; 56(1 suppl 1): 47-49.
3. Higa R: Colorectal cancer: epidemiology and primary profilaxis. Acta Gastroenterol Latinoam 2011; 41: 70-73[in Spanish].
4. Cao Y, Prescott SM: Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 2002; 190: 279-286
5. Grkovich A, Johnson CA, Buczynski MW, et al: Lipopolysaccharide-induced cyclooxygenase-2 expression in human U937 macrophages is phosphatidic acid phosphohydrolase-1dependent. J Biol Chem 2006; 281: 32978-32987.
6. Hirsch E, Filipovich Y, Mahendroo M: Signaling via the type I IL-1 and TNF receptors is necessary for bacterially induced preterm labor in a murine model. Am J Obstet Gynecol 2006; 194: 1334-1340.
7. Tammali R, Ramana KV, Singhal SS, et al: Aldose reductase regulates growth factorinduced cyclooxygenase-2 expression and prostaglandin E2 production in human colon cancer cells. Cancer Res 2006; 66: 9705-9713
8. Soslow RA, Dannenberg AJ, Rush D, et al: COX2 is expressed in human pulmonary, colonic and mammary tumors. Cancer 2000; 89: 2637-2645.
9. Brabender J, Park J, Metzger R, et al: Prognostic significance of cyclooxygenase 2 Mrna expression in non-small cell lung cancer. Ann Surg 2002; 235: 440-443.
10. Lim SJ, Kim HJ, Kim JY, et al: Expression of HuR is associated with increased cyclooxygenase-2 expression in uterine cervical carcinoma. Int J Gynecol Pathol 2007; 26: 229-234.
11. Urakawa H, Nishida Y, Naruse T, et al: Cyclooxygenase-2 overexpression predicts poor survival in patients with high-grade extremity osteosarcoma: a pilot study. Clin Orthop Relat Res 2009; 467: 2932-2938.
12. Xiao H, Zhang Q, Lin Y, et al: Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. Int J Cancer 2008; 122: 2115-2124.
13. Gradilone A, Pulcinelli FM, Lotti LV, et al: Celecoxib upregulates multidrug resistance proteins in colon cancer: lack of synergy with standard chemotherapy. Curr Cancer Drug Targets 2008; 8: 414-420.
14. Zhu FS, Chen XM, Wang YJ, et al: Antitumor effects of specific cyclooxygenase inhibitors combined with chemotherapeutic agents on gastric cancer cells in vitro. Zhonghua Zhong Liu Za Zhi 2007; 29: 186-188 [in Chinese, English abstract].
15. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
16. Owusu C, Koroukian SM, Schluchter M, et al: Screening older cancer patients for a Comprehensive Geriatric Assessment: a comparison of three instruments. J Geriatr Oncol 2011; 2: 121-129.
17. Schag CC, Heinrich RL, Ganz PA: Karnofsky performance status revisited: reliability, validity and guidelines. J Clin Oncol 1984; 2: 187-193.
18. Cheng AS, Chan HL, Leung WK, et al: Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in upregulation of COX-2. Mod Pathol 2004; 17: 1169-1179.
19. Goldberg RM, Meropol NJ, Tabernero J, et al: Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer. Gastrointest Cancer Res 2009; 3(5 suppl 2): S23-S27.
20. Waisberg DR, Fava AS, Martins LC, et al: Colonic carcinoid tumors: a clinicopathologic study of 23 patients from a single institution. Arq Gastroenterol 2009; 46: 288-293.
21. Goldstein JL, Silverstein FE, Agrawal NM, et al: Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000; 95: 1681-1690.
22. Johnson GL, Lapadat R: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002; 298: 1911-1912.
23. Elder DJ, Halton DE, Playle LC, et al: The MEK/ERK pathway mediates COX-2-selective NSAID-induced apoptosis and induced COX-2 protein expression in colorectal carcinoma cells. Int J Cancer 2002; 99: 323-327.
24. Liu XH, Yao S, Kirschenbaum A, et al: NS398, a selective yclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 1998; 58: 4245-4249.
25. Venkatesan P, Puvvada N, Dash R, et al: The potential of celecoxib-loaded hydroxyapatitechitosan nanocomposite for the treatment of colon cancer. Biomaterials 2011; 32: 3794-3806.
26. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
27. Choy H, Milas L: Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? J Natl Cancer Inst 2003; 95: 1440-1452.
28. Huang JX, Xiao W, Chen WC, et al: Relationship between COX-2 and cell cycleregulatory proteins in patients with esophageal squamous cell carcinoma. World J Gastroenterol 2010; 16: 5975-5981.
29. Hyde CA, Missailidis S: Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumourangiogenesis. Int Immunopharmacol 2009; 9: 701-715.
30. Hermanova M, Karasek P, Tomasek J, et al: Comparative analysis of clinicopathological correlations of cyclooxygenase-2 expression in resectable pancreatic cancer. World J Gastroenterol 2010; 16: 1879-1884.
31. Bertagnolli MM, Eagle CJ, Zauber AG, et al: Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila) 2009; 2: 310-321.
32. Madan RA, Xia Q, Chang VT, et al: A retrospective analysis of cardiovascular morbidity in metastatic hormone-refractory prostate cancer patients on high doses of the selective COX-2 inhibitor celecoxib. Expert Opin Pharmacother 2007; 8: 1425-1431.
33. Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 954-959.
34. White WB, Faich G, Whelton A, et al: Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002; 89: 425-430.
35. Gasparini G, Longo R, Sarmiento R, et al: Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol 2003; 4: 605-615.
36. Williams CS, Tsujii M, Reese J, et al: Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000; 105: 1589-1594.
37. Shin YK, Park JS, Kim HS, et al: Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Cancer Res 2005; 65: 9501-9509.
38. Palayoor ST, Arayankalayil MJ, Shoaibi A, et al: Radiation sensitivity of human carcinoma cells transfected with small interfering RNA targeted against cyclooxygenase-2. Clin Cancer Res 2005; 11: 6980-6986.
39. Piazza GA, Alberts DS, Hixson LJ, et al: Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 1997; 57: 2909-2915.
40. kip1 and cell cycle arrest. Cancer Res 2004; 64: 1369-1376.
41. Grösch S, Tegeder I, Niederberger E, et al: COX 2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001; 15: 2742-2744.
42. Maier TJ, Schilling K, Schmidt R, et al: Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol 2004; 67: 1469-1478.
43. Richter M, Weiss M, Weinberger I, et al: Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors. Carcinogenesis 2001; 22: 17-25.
44. Patel MI, Subbaramaiah K, Du B, et al: Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 2005; 11: 1999-2007.
45. Grösch S, Maier TJ, Schiffmann S, et al: Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 2006; 98: 736-747.
46. Yu J, Tang BD, Leung WK, et al: Different cell kinetic changes in rat stomach cancer after treatment with celecoxib or indomethacin: implications on chemoprevention. World J Gastroenterol 2005; 11: 41-45.
47. Altorki NK, Port JL, Zhang F, et al: Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer. Clin Cancer Res 2005; 11: 4191-4197.
48. Irie T, Tsujii M, Tsuji S, et al: Synergistic antitumor effects of celecoxib with 5fluorouracil depend on IFN-γ. Int J Cancer 2007; 121: 878-883.